Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

BACKGROUND: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has been intensively studied to lower low-density lipoprotein cholesterol (LDL-C) levels. The purpose of this meta-analysis was to evaluate the safety and efficacy of anti-PCSK9 antibodies in randomized, controlled trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin-Lin, Zhu, Qing-Qing, Zhu, Li, Chen, Jian-Zhou, Chen, Qin-Hua, Li, Guan-Nan, Xie, Jun, Kang, Li-Na, Xu, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477483/
https://www.ncbi.nlm.nih.gov/pubmed/26099511
http://dx.doi.org/10.1186/s12916-015-0358-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477483/
https://www.ncbi.nlm.nih.gov/pubmed/26099511
http://dx.doi.org/10.1186/s12916-015-0358-8

Ejemplares similares